At the 2021 Pujiang Innovation Forum plenary meeting held today (June 3), Chen Wei, an academician of the Chinese Academy of Engineering and a researcher of the Academy of Military Sciences, revealed in her speech that she led a team to develop an inhaled recombinant new coronavirus vaccine in cooperation with Cansino ( Adenovirus vector), which is currently applied for emergency use as authorized by the State Food and Drug Administration.
This new crown vaccine adopts aerosol delivery method, and the required dose is only 1/5 of the injectable adenovirus vector vaccine, which can form mucosal immunity, and is expected to reduce the cost of vaccination and improve the accessibility of the vaccine.
“I have a’revolutionary ideal’, that is to make a non-injection, non-cold-chain’dual non-vaccine’.” Academician Chen Wei told the audience. Nowadays, non-injectable vaccines with more convenient and lower cost have been born, and they are expected to be approved for marketing in the near future.
A video played on the forum showed a citizen who participated in a clinical trial inhaling the aerosolized vaccine sprayed from the device.
According to reports, the inhaled adenovirus vector vaccine is the same as the injectable adenovirus vector vaccine that received conditional approval for the market in February this year in terms of virus seed, cell bank, stock solution production process , formula, etc.,. Different, the former uses aerosolized inhalation immunization special equipment for vaccination, so that the atomized vaccine tiny particles can enter the human respiratory tract and lungs
Source : Baidu News